CM
SLNO

Crestline Management’s Soleno Therapeutics SLNO Stock Holding History

Crestline Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,943
Closed -$582K – 542
2024
Q4 		$582K Buy
+12,943
New +$671K 0.02% 510

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crestline Management's SLNO Position: Q1 2025 in Review

Crestline Management sold out of Soleno Therapeutics (SLNO) in Q1 2025, closing a stake of 12,943 shares — an estimated $582K sold.

Crestline Management first reported a position in SLNO in Q4 2024 and held it in 1 quarter. The position peaked at $582K in Q4 2024. 217 funds tracked by Wall St. Rank hold SLNO as of Q1 2025.

  • Crestline Management reported no remaining Soleno Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 12,943 Soleno Therapeutics shares in Q1 2025, an estimated $582K.
  • Crestline Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Soleno Therapeutics position peaked at $582K in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.